Carisma Therapeutics Reports Phase 1 CT-0508 Data Showing Safety and Biomarker Correlation

Carisma Therapeutics Inc.

CT-0508 is a HER2-targeted CAR-M therapy for HER2 overexpressing cancers; 14 patients treated across group 1 (n=9) and group 2 (n=5).
Group 1: best overall response of stable disease in 4 of 9 patients; group 2: best overall response was progressive disease.
No dose-limiting toxicities reported; CT-0508 well-tolerated after single-day bolus infusion in group 2.
Translational analyses combining groups show correlation between TME activation, T cell activation, and HER2 status with stable disease.
Company to focus on combination sub-study with pembrolizumab due to T cell exhaustion findings from trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.